share_log

Investors in Shanghai Hile Bio-Technology (SHSE:603718) From Three Years Ago Are Still Down 44%, Even After 10% Gain This Past Week

Investors in Shanghai Hile Bio-Technology (SHSE:603718) From Three Years Ago Are Still Down 44%, Even After 10% Gain This Past Week

三年前投资海利生物(SHSE:603718)的投资者仍然亏损44%,即便在过去一周获利了10%
Simply Wall St ·  10/05 21:28

While not a mind-blowing move, it is good to see that the Shanghai Hile Bio-Technology Co., Ltd. (SHSE:603718) share price has gained 21% in the last three months. But that cannot eclipse the less-than-impressive returns over the last three years. Truth be told the share price declined 45% in three years and that return, Dear Reader, falls short of what you could have got from passive investing with an index fund.

尽管这并不是一个令人瞠目结舌的举动,但值得一提的是,上海海利生物科技股份有限公司(SHSE:603718)股价在过去三个月内上涨了21%。但无法掩盖在过去三年中不甚理想的回报。实话实说,股价在三年内下跌了45%,亲爱的读者,这种回报远不及您从指数基金 passivetrade with an index fund 获得的回报。

The recent uptick of 10% could be a positive sign of things to come, so let's take a look at historical fundamentals.

最近的10%上涨可能是未来好转的积极信号,所以让我们来看看历史基本面。

To quote Buffett, 'Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace...' One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.

引用巴菲特的话:“船只将周游世界,而‘地平派’仍会兴旺。市场上的价格和价值仍会存在广泛的差距……”考虑一家公司在市场上的认知如何变化的一个不完美但简单的方法是比较每股收益(EPS)的变化和股价的波动。

Shanghai Hile Bio-Technology saw its share price decline over the three years in which its EPS also dropped, falling to a loss. Since the company has fallen to a loss making position, it's hard to compare the change in EPS with the share price change. However, we can say we'd expect to see a falling share price in this scenario.

上海海利生物科技在过去三年中股价下跌,同时每股收益也下降,陷入亏损。由于公司已经陷入亏损的境地,很难将每股收益的变化与股价的变化进行比较。但我们可以说,在这种情况下,我们预计会看到股价下跌。

The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image).

下图显示了EPS随时间变化的情况(点击图像以显示确切值)。

big
SHSE:603718 Earnings Per Share Growth October 6th 2024
2024年10月6日的每股收益增长

It might be well worthwhile taking a look at our free report on Shanghai Hile Bio-Technology's earnings, revenue and cash flow.

您可能会发现我们关于上海海利生物的收入、营业收入和现金流的免费报告非常值得一看。

A Different Perspective

不同的观点

Investors in Shanghai Hile Bio-Technology had a tough year, with a total loss of 30% (including dividends), against a market gain of about 3.3%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 7% over the last half decade. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Even so, be aware that Shanghai Hile Bio-Technology is showing 1 warning sign in our investment analysis , you should know about...

上海海利生物的投资者经历了艰难的一年,包括分红在内,总损失达30%,而市场收益约为3.3%。 但请记住,即使是最好的股票有时也会在十二个月内表现不佳。不幸的是,去年的表现可能表明存在未解决的挑战,因为它比过去半个世纪的年化损失7%更糟。我们意识到巴伦·罗斯柴尔德曾说过投资者应该在“街上有血的时候买入”,但我们警告投资者应首先确定他们正在购买优质的业务。我发现长期关注股价作为业务表现的一种替代方式非常有趣。但要真正获得洞察力,我们也需要考虑其他信息。即便如此,请注意,我们的投资分析显示上海海利生物展示了1个警告信号,您应该了解...

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.

如果您愿意查看另一家公司(具有潜在的更好财务状况),请不要错过这个免费的公司列表,证明它们可以增长收益。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

请注意,本文引用的市场回报反映了目前在中国交易所上市的股票的市场加权平均回报。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发